Myriad Genetics (MYGN) Projected to Post Earnings on Wednesday

Myriad Genetics (NASDAQ:MYGN) is projected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Myriad Genetics to announce earnings of ($0.17) per share and revenue of $191.33 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.19). The firm had revenue of $190.70 million during the quarter, compared to analyst estimates of $206.03 million. The firm’s revenue for the quarter was down 10.5% on a year-over-year basis. During the same period last year, the business posted $0.05 EPS. On average, analysts expect Myriad Genetics to post ($0.99) EPS for the current fiscal year and ($0.93) EPS for the next fiscal year.

Myriad Genetics Stock Up 4.5%

NASDAQ:MYGN opened at $6.29 on Wednesday. The business’s 50-day moving average price is $4.01 and its 200 day moving average price is $4.62. Myriad Genetics has a 52-week low of $2.74 and a 52-week high of $8.38.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wells Fargo & Company set a $4.50 price target on shares of Myriad Genetics in a report on Tuesday, October 20th. Weiss Ratings raised shares of Myriad Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 12th. Piper Sandler raised shares of Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 price objective on the stock in a research note on Tuesday, October 20th. Craig Hallum boosted their target price on shares of Myriad Genetics from $4.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Finally, TD Cowen increased their target price on shares of Myriad Genetics from $4.00 to $4.50 and gave the company a “hold” rating in a research note on Tuesday, October 13th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Myriad Genetics presently has an average rating of “Hold” and an average target price of $4.77.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.